Reference is made to the announcement made on 27 October 2023 regarding the
transfer of 1,900,219 shares in Medistim ASA from Aeternum Capital AS to its
100% owned subsidiary, Acapital MEDI HoldCo AS ("HoldCo"), by way of a capital
contribution in kind.
As part of requests for in-specie redemption in Aeternum Capital AS by certain
of its investors, a capital reduction in Aeternum Capital AS has been resolved
by way of a distribution in kind of 8,154,977 shares in HoldCo from Aeternum
Capital AS to the investors which have requested redemption, equal to approx.
81.55% of the votes and capital in HoldCo. The creditor notice period for such
capital reduction expired today. The transfer of the shares in HoldCo will occur
upon registration of the capital reduction with the Norwegian Business Registry,
expected to occur in early 2024.
As part of the redemption, 7,980,813 shares in HoldCo are distributed from
Aeternum Capital AS to WQZ Investment Group Ltd., equal to approx. 79.81% of the
votes and capital in HoldCo.
Following the transfer of the shares in HoldCo, WQZ Investment Group Ltd. will
be the majority shareholder with controlling voting rights in HoldCo and will be
the indirect holder of the 1,900,219 shares in Medistim ASA, equal to approx.
10.36% of the shares and votes in Medistim ASA.
Aeternum Capital AS and other companies managed by Aeternum Management AS will
be a minority shareholder in HoldCo and will as such no longer have indirect
control over the shares held by HoldCo in Medistim ASA.
Aeternum Capital AS is managed by Aeternum Management AS, while WQZ Investment
Group Ltd. is indirectly controlled by trusts established by John Fredriksen for
the benefit of his family.
No other rights to shares in Medistim ASA are held directly or indirectly by any
of the above mentioned entities.
Aeternum Capital AS is a closely associated person of Anthea Arff-Pettersen,
board member and primary insider in Medistim ASA. Please see attached form for
further details.
This information is subject to the disclosure requirements pursuant to Article
19 of the EU Market Abuse Regulation and Sections 4-2, cf. 5-12 of the Norwegian
Securities Trading Act.